Remifentanil
Remifentanil, Ultiva (remifentanil) is a small molecule pharmaceutical. Remifentanil was first approved as Ultiva on 1996-07-12. It is used to treat pain in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Remifentanil, Ultiva
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| remifentanil hydrochloride | ANDA | 2024-09-12 |
| remifentanil hydrochloride remifentanil hydrochloride | ANDA | 2020-10-16 |
| ultiva | New Drug Application | 2023-12-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
984 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anesthesia | D000758 | — | — | 3 | 4 | 13 | 31 | 74 | 123 |
| Postoperative pain | D010149 | — | G89.18 | — | 2 | 4 | 26 | 40 | 72 |
| General anesthesia | D000768 | — | — | — | 1 | 3 | 10 | 43 | 57 |
| Pain | D010146 | EFO_0003843 | R52 | 2 | — | 1 | 12 | 31 | 46 |
| Emergence delirium | D000071257 | — | — | 2 | 1 | 1 | 7 | 20 | 30 |
| Delirium | D003693 | — | R41.0 | 2 | 1 | 1 | 6 | 19 | 28 |
| Intravenous anesthesia | D000771 | — | — | — | — | 2 | 7 | 19 | 28 |
| Hyperalgesia | D006930 | — | — | 1 | 3 | 1 | 11 | 11 | 27 |
| Analgesia | D000698 | — | — | — | — | 3 | 4 | 18 | 25 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 5 | 9 | 14 |
Show 194 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Wounds and injuries | D014947 | — | T14.8 | — | — | 1 | — | 7 | 8 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 5 | 6 |
| Scoliosis | D012600 | EFO_0004273 | M41 | — | 3 | 1 | — | 1 | 5 |
| Anesthesia and analgesia | D000760 | — | — | — | 1 | 2 | — | 2 | 4 |
| Septic shock | D012772 | — | A48.3 | — | — | 2 | — | 2 | 4 |
| Shock | D012769 | — | R57.1 | — | — | 2 | — | 2 | 4 |
| Muscle hypotonia | D009123 | HP_0001319 | — | — | 1 | 1 | — | 1 | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 1 | — | 1 | 3 |
| Neurotoxicity syndromes | D020258 | — | G92 | — | — | 1 | — | 2 | 3 |
| Breast diseases | D001941 | — | N60-N65 | — | — | 1 | — | 2 | 3 |
Show 22 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | 4 | 5 |
| Hysterectomy | D007044 | EFO_0003881 | — | — | 1 | — | — | 3 | 4 |
| Spinal fusion | D013123 | — | — | — | 1 | — | — | 1 | 2 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | — | — | — | 1 |
| Spondylolisthesis | D013168 | EFO_0007493 | M43.1 | — | 1 | — | — | — | 1 |
| Morphine dependence | D009021 | EFO_0005612 | — | — | 1 | — | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | — | — | — | 1 |
| Fibrosis | D005355 | — | — | — | 1 | — | — | — | 1 |
| Hallux valgus | D006215 | HP_0001822 | — | — | 1 | — | — | — | 1 |
| Ventilator weaning | D015300 | — | — | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Femur head necrosis | D005271 | — | — | 1 | — | — | — | — | 1 |
| Necrosis | D009336 | — | — | 1 | — | — | — | — | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Opiate overdose | D000083682 | — | — | 1 | — | — | — | — | 1 |
| Tympanic membrane perforation | D018058 | — | H72 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 9 | 9 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | — | 7 | 7 |
| Pharyngitis | D010612 | — | R07.0 | — | — | — | — | 6 | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 6 | 6 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 6 | 6 |
| Colorectal neoplasms | D015179 | — | — | — | — | — | — | 6 | 6 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | — | — | 6 | 6 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | — | 5 | 5 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 5 | 5 |
| Patient satisfaction | D017060 | — | — | — | — | — | — | 4 | 4 |
Show 207 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Remifentanil |
| INN | remifentanil |
| Description | Remifentanil is a piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline. It has a role as a mu-opioid receptor agonist, an opioid analgesic, an intravenous anaesthetic and a sedative. It is an anilide, a piperidinecarboxylate ester, a monocarboxylic acid amide and an alpha-amino acid ester. |
| Classification | Small molecule |
| Drug class | narcotic analgesics (fentanyl derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(=O)N(c1ccccc1)C1(C(=O)OC)CCN(CCC(=O)OC)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 132875-61-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1005 |
| ChEBI ID | 8802 |
| PubChem CID | 60815 |
| DrugBank | DB00899 |
| UNII ID | P10582JYYK (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,921 documents
View more details
Safety
Black-box Warning
Black-box warning for: Remifentanil hydrochloride, Remifentanil hydrochloride remifentanil hydrochloride, Ultiva
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,587 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use